Abstract
Patients treated with conventional cancer chemotherapy suffer from side effects of the drugs due to non-selective action of chemotherapeutic drugs to normal cells. Active targeting nanoparticles that are conjugated to targeting ligands on the surface of nanoparticles play an important role in improving drug selectivity to the cancer cell. Several chemotherapeutic drugs and traditional/herbal medicines reported for anticancer activities have been investigated for their selective delivery to cancer cells by active targeting nanoparticles. This systematic review summarizes reports on this application. Literature search was conducted through PubMed database search up to March 2017 using the terms nanoparticle, chemotherapy, traditional medicine, herbal medicine, natural medicine, natural compound, cancer treatment, and active targeting. Out of 695 published articles, 61 articles were included in the analysis based on the predefined inclusion and exclusion criteria. The targeting ligands included proteins/peptides, hyaluronic acid, folic acid, antibodies/antibody fragments, aptamer, and carbohydrates/polysaccharides. In vitro and in vivo studies suggest that active targeting nanoparticles increase selectivity in cellular uptake and/or cytotoxicity over the conventional chemotherapeutic drugs and non-targeted nanoparticle platform, particularly enhancement of drug efficacy and safety. However, clinical studies are required to confirm these findings.
Introduction
Cancer remains one of the major causes of deaths worldwide. In 2017, approximately 1.7 million new cases and 600 thousand deaths were estimated to occur in the USA.Citation1 Most patients treated with conventional chemotherapy suffer from serious side effects due to non-selective action of chemotherapeutic drugs to normal cells. For a few decades, nanoparticles have been developed as a drug delivery system of various chemotherapeutic drugs to enhance drug efficacy and safety.Citation2–Citation4 Nanoparticles play an important role in increasing drug concentration in cancer cells by enhancing drug accumulation by passive and active targeting mechanisms as well as by decreasing drug efflux from cancer cells. The passive targeting nanoparticle is the mechanism by which the drugs leak from blood vessels supplying cancer cells and accumulate in the cells by enhanced permeability and retention (EPR) effect.Citation5 The active targeting nanoparticles, on the other hand, target ligands conjugated on the surface of nanoparticles, resulting in increasing cellular uptake by receptor-mediated endocytosis and therefore increased drug accumulation in cancer cells. This mechanism relies on the interaction between tumor ligands conjugated on the surface of nanoparticles and cell-surface receptors or antigens on cancer cell surfaces ().Citation5 Nanoparticles acting via both mechanisms have been shown to increase drug concentration in cancer cells. Active targeting nanoparticles have been shown in various studies to be more efficient in increasing drug accumulation in cancer cells and therefore play important role not only in modern cancer chemotherapy, but also in cancer therapy with traditional/herbal medicines.Citation6–Citation11 A number of nanoparticle formulations derived from these active compounds have been developed for active targeting purpose to improve anticancer efficacy and to reduce side effects. The objective of this current review is to summarize the research articles relating to the application of active targeting nanoparticles delivering system for chemotherapeutic drugs derived from chemical synthesis as well as natural sources.
Figure 1 Passive targeting and active targeting mechanisms of nanoparticles.
Materials and methods
Study selection and inclusion and exclusion criteria
This systematic review was conducted through the search from PubMed database up to March 2017. The following keywords were used: nanoparticle, chemotherapy, traditional medicine, herbal medicine, natural medicine, natural compound, cancer treatment, and active targeting. Inclusion criteria for selection of the searched articles were 1) articles in full text and written in English; 2) articles with in vitro or in vivo investigations of effects of nanoparticles delivering chemotherapeutic drugs or traditional/herbal medicines on efficacy and/or safety; and 3) articles with investigations of targeting and receptor/antigen. The articles with insufficient data for extraction or those with application for radiotherapy, gene therapy, photodynamic therapy, or for diagnostic purpose, or duplicate articles, or review articles were excluded from the analysis.
Data extraction and collection
The titles and abstracts of articles searched from PubMed database using the above mentioned keywords were initially screened to obtain relevant original research articles according to the eligibility criteria. Thereafter, the full texts of all relevant articles were carefully examined in details to confirm their compliance with the defined eligibility criteria. The studies of active targeting nanoparticles applied for both chemotherapeutic drugs and traditional/herbal medicines for cancer were classified according to the types of targeting ligands.
Results
Study description
Twenty out of 695 research articles were initially excluded from the analysis during title screening for duplicate articles. The titles together with abstracts of the remaining articles were further checked for eligibility criteria and a total of 597 articles were excluded from the analysis. Finally, 61 out of 78 articles were included in the analysis, 17 articles being excluded due to unclear/inadequate information. The flow diagram of the search process is presented in , and the effects of active targeting nanoparticles delivering modern chemotherapeutic drugs and traditional/herbal medicines for cancer are summarized in and .
Table 1 Summary of research articles that investigated active targeting NPs delivering chemotherapeutic drugs in cancer therapy
Table 2 Summary of research articles that investigated active targeting NP delivering traditional/herbal medicines in cancer therapy
Figure 2 Flow diagram showing the different phases of the systematic review.
Of the 61 articles included in the analysis, 54 (88.5%) investigated nanoparticles delivering modern chemotherapeutic drugs; the majority was doxorubicin (40.7%), followed by paclitaxel (8.5%). Types of targeting ligand platforms used included proteins or small peptides (15 articles), hyaluronic acids (HAs; 10 articles), folic acids (9 articles), antibodies (5 articles), aptamers (5 articles), carbohydrates or polysaccharide (5 articles), and other molecules (5 articles). Seven articles (11.5%) investigated nanoparticles delivering traditional/herbal medicines; the majority was curcumin (42.9%). The ligand platforms used were proteins or small peptides (2 articles), HA (1 article), folic acid (1 article), antibody (1 article), aptamer (1 article), and other molecule (1 article).
Discussion
Ligands for nanoparticle platform
Proteins or small peptides
Various types of proteins or small peptides were used to conjugate on the surface of nanoparticles to improve selectivity of chemotherapeutic drugs or traditional/herbal medicines to cancer cells. Transferrin, a serum glycoprotein, was one of the widely used targeting ligands. It plays a role in transferring iron from blood stream into the cells by binding to transfer-rin receptor on the cell surface. Upregulation of transferrin receptor has been reported in metastatic and drug-resistant cancer cells.Citation67 The transferrin-conjugating nanoparticles delivering chemotherapeutic drugs have been shown to improve cellular uptake of the drugs by cancer cells and enhance in vitro and in vivo cytotoxicity. For instance, the transferrin-conjugated polyethylene glycol (PEG) nano-particle delivering hydroxycamptothecin was shown to provide longer retention time of drug in blood circulation, higher drug accumulation in cancer cells, and higher in vivo growth inhibitory activity against S180 tumor compared with non-targeted nanoparticles.Citation16 In the study of transferrin-conjugated chitosan-PEG nanoparticles delivering paclitaxel, the targeted nanoparticles also exhibited higher cytotoxic activity to transferrin-overexpressing human non-small cell lung cancer cells (HOP-62). The respective half-maximal inhibitory concentrations (ICs50) were 0.3 µM and 2.0 µM.Citation17 Apart from transferrin, arginine–glycine–aspartic acid (RGD) peptide has been used as targeting ligand to conjugate on the surface of nanoparticles to specifically target integrin αvβ3 receptor. This receptor is expressed on the surface of tumor vessels and various types of cancer cells and plays important roles in tumor growth promotion, metastasis, and angiogenesis.Citation18 A number of RGD-conjugated nanoparticles delivering chemotherapeutic drugs or traditional/herbal medicines have been developed and demonstrated to promote their delivery to the cancer cells. The cyclic arginine–glycine–aspartic acid–tyrosine–lysine c(RGDyK)-conjugated poly(trimethylene carbonate)-PEG micellar nanoparticle delivering paclitaxel was shown to enhance cytotoxic activity of the drug to integrin αvβ3-overexpressing human glioblastoma cells (U87MG) compared with non-targeted nanoparticles and free drugs (mean IC50: 0.022 µg/mL, 0.051 µg/mL, and 0.058 µg/mL, respectively). The targeted nanoparticles also exhibited greater activity on cell apoptosis (11.23% vs 8.31% and 8.03% vs 5.38% inhibition, for early and late apoptosis, respectively). The percentages (mean values) of free drug were 6.67% and 4.32%, respectively. In addition, cellular drug uptake by U87MG cells was significantly increased.Citation18 Superior cytotoxic potency against integrin αvβ3-overexpressing human cervical carcinoma cells (HeLa) together with increased cellular uptake was also demonstrated with RGD-conjugated magnetic iron oxide nanoparticles (MIONPs)-PEG delivering doxorubicin compared with free drug and non-targeted MIONPs.Citation19 In another study, improved cytotoxic activity by the cRGDyK-conjugated poly(2-ethyl-2-oxazoline)-poly(d,l-lactide) nanoparticles delivering paclitaxel over the non-targeted nanoparticles and free drug was reported (mean IC50: 51.16 ng/mL, 64.53 ng/mL, and 62.95 ng/mL, respectively). The enhanced activity was through direct targeting of the integrin αvβ3-overexpressing prostate cancer cells (PC-3), as well as increasing of cellular uptake by PC-3 cells. Moreover, the targeted nanoparticle was also shown to enhance in vivo tumor growth inhibition rate in PC-3 tumor-bearing mice.Citation20
Other types of peptides that have been applied for conjugation on the surface of nanoparticles to increase selectivity of chemotherapeutic drugs to cancer cells include bombesin peptide-conjugated poly(lactic-co-glycolic acid) (PLGA) and NR7 peptide-conjugated PLGA-PEG nanoparticles. Bombesin-conjugated nanoparticles delivering docetaxel specifically bind to gastrin-releasing peptide receptor, which is overexpressed on cell surfaces of prostate, breast, ovarian, pancreatic, and colorectal cancers.Citation22,Citation68 This targeted nanoparticle was shown to enhance cytotoxic activity of the drug to the gastrin-releasing peptide receptor overexpressing human breast cancer cells (MDA-MB-231) compared with non-targeted nanoparticles (mean IC50: 35.53 ng/mL and 142.23 ng/mL, respectively).Citation22 The NR7 peptide-conjugated PLGA-PEG nanoparticle delivering doxorubicin was used for specific drug binding to epidermal growth factor receptor (EGFR) on the cancer cell surface.Citation23 The EGFR is a known receptor that is overexpressed on various types of cancer cell surfaces including head and neck, renal, ovarian, breast, and non-small-cell lung cancer.Citation47,Citation69 Activation of this receptor results in inhibition of cell apoptosis, promotion of cell proliferation, triggering of angiogenesis, and enhancement of tumor survival and metastasis. Therefore, inhibition of the function of this receptor would be expected to benefit cancer treatment. The NR7 peptide-conjugated PLGA-PEG nanoparticles exhibited higher cytotoxic activity against human ovarian carcinoma cells (SKOV3) compared with non-targeted nanoparticles (mean IC50: 0.05 µg/mL and 3.12 µg/mL, respectively).Citation23 Although most studies demonstrated satisfactory outcomes of peptide- or protein-conjugated nanoparticles on targeting cancer cells, one study reported that H2009.1 peptide-conjugated liposome delivering doxorubicin to cancer cells expressing integrin αvβ6 receptor could not improve the efficacy of the drug. This was due to the liposome platform preventing the targeting ligand from binding to the receptor on the cancer cell surface, and resulted in relatively low drug accumulation in cancer cells.Citation12
Hyaluronic acid
HA is a negatively charged linear glycosaminoglycan that consists of d-glucuronic acid and N-acetyl-d-glucosamine. It can specifically bind to CD44 receptor that is overexpressed on the cell surface of various types of cancer including lung, breast, colon, prostate, gastric, and head and neck cancers.Citation70 HA is a widely used targeting ligand to conjugate on the surface of nanoparticles to improve selectivity of chemotherapeutic drugs to cancer cells and enhance drug efficacy and safety. In one study, HA with the two molecular weights, ie, 9.5 kDa and 35 kDa, was used to conjugate polymeric micelles delivering paclitaxel. The conjugate using 9.5 kDa HA was found to effectively increase drug cellular uptake by CD44-overexpressing human breast adenocarcinoma cells (MCF-7) compared with 35 kDa HA. In murine hepatic carcinoma (Heps), it also exhibited tumor growth inhibition at a higher rate and greater accumulation at the tumor site compared with other nanoparticle formulations.Citation27 These results suggest that the molecular weight of HA directly influenced the efficacy of drug-loaded active targeting nanoparticles. The HA-conjugated chitosan nanoparticle delivering cisplatin was shown to increase drug cellular uptake by CD44-positive human lung cancer cells (A549) and effectively enhance cytotoxic activity of the drug, compared with non-targeted nanoparticles.Citation28 The HA-conjugated liquid crystalline nanoparticle delivering rapamycin was reported to increase cytotoxic activity of the drug to CD44-overexpressing human breast adenocarcinoma cells (MDA-MB-231) compared with non-targeted nanoparticles (mean IC50: 18 µg/mL and 24.3 µg/mL, respectively). Moreover, the targeted nanoparticles also enhanced in vivo tumor growth inhibition rate in Ehrlich ascites tumor-bearing mice.Citation29
For traditional/herbal medicines, HA has also been used for conjugation on the surface of nanoparticles delivering 3,4-difluorobenzylidene curcumin resulting in increased cellular uptake and cytotoxic activity of the drug against human pancreatic cancer cells (MiaPaCa-2 and AsPC-1) compared with non-targeted nanoparticles (mean IC50: 140 nM, 160 nM, and 245 nM, respectively). Interestingly, when the CD44 receptor was blocked by free soluble HA, the cytotoxic activity to MiaPaCa-2 cells was comparable between the targeted and non-targeted nanoparticles (mean IC50: 234 nM and 245 nM, respectively).Citation63 These results confirm that targeting ligand-conjugated nanoparticles enhances drug efficacy by improving cellular uptake through receptor-mediated endocytosis mechanism.
Folate
Folate or vitamin B9 is a stable and poorly immunogenic water-soluble vitamin. It is essential for DNA synthesis and replication, methylation, cell division and growth, and cell survival, particularly in rapidly dividing cells or cancer cells.Citation71 Folic acid receptor is overexpressed on several cancer cell surfaces including ovarian, cervical, breast, lung, kidney, colorectal, and brain cancers.Citation71 Using folic acid as cancer cell targeting of chemotherapeutic drug nanocarriers has been demonstrated in various studies to improve drug efficacy and safety profiles. The folic acid-conjugated PEG-PLGA nanoparticle delivering docetaxel was shown to increase drug cellular uptake by human cervical carcinoma cells (HeLa) with enhanced cytotoxic activity compared with free drug (mean IC50: 0.69 µg/mL and 8.29 µg/mL, respectively). It also significantly inhibited tumor growth in HeLa tumor-bearing mice.Citation36 The folic acid-conjugated albumin nanoparticle delivering gemcitabine was shown to enhance cytotoxic activity of the drug against folic acid receptor-overexpressing human breast adenocarcinoma cells (MCF-7) compared with non-targeted nanoparticles (mean IC50: 0.175 µM and 0.240 µM, respectively). Similarly, in folic acid receptor-overexpressing human ovarian cancer cells (Ovcar-5), the targeted nanoparticles exhibited superior cytotoxic activity over the non-targeted nanoparticles (mean IC50: 0.173 µM and 0.279 µM, respectively). On the other hand, activity of the targeted nanoparticles was found similar to that of non-targeted nanoparticles against folate receptor expressing human pancreatic cancer cells (MIAPaCa-2) (mean IC50: 0.166 µM and 0.169 µM, respectively).Citation38 In one study, the folic acid-conjugated PEG-PLGA nanoparticle delivering paclitaxel was shown to increase drug cellular uptake by folic acid-overexpressing human endometrial carcinoma cells (HEC-1A) with superior cytotoxic activity over the non-targeted nanoparticle (mean IC50: 3.43 µg/mL and 8.81 µg/mL, respectively). Moreover, it also produced significantly higher cell apoptotic activity compared with non-targeted and free drug (35.94%, 23.97% and 19%, respectively). In vivo, it produced significant tumor growth inhibition in HEC-1A tumor-bearing mice.Citation43 For traditional/herbal medicines, folic acid-conjugated poly(epsilon-caprolactone)-PEG-poly (epsilon-caprolactone) nanoparticle delivering honokiol, a traditional Chinese medicine, was shown to increase compound cellular uptake by folic acid-overexpressing human nasopharynx carcinoma cells (HNE-1) with enhanced cytotoxic activity compared with free drug (mean IC50: 18.41 µg/mL and 38.59 µg/mL, respectively). Furthermore, the targeted nanoparticles also resulted in significant cell apoptotic activity compared with non-targeted nanoparticles (86.07% and 70.89%, respectively) and prolongation of median survival time compared with non-targeted nanoparticles and free drug (median survival time: 57.5 days, 42.5 days, and 34 days, respectively).Citation11
Antibodies or antibody fragments
Antibodies or antibody fragments are one of the first targeting ligands used for conjugation on the surface of nanoparticles to target cancer cells due to their potential to specifically bind to antigens or receptors on cancer cell surfaces with high affinity. Various types of antibodies or antibody fragments have been used as targeting agents including anti-CD20 monoclonal antibody, anti-CD47 monoclonal antibody, EGFR antibody, and anti-Fas monoclonal antibody. These targeted nanoparticles have been shown to improve cellular uptake by cancer cells and enhance cytotoxic activity of the drugs to cancer cells. For instance, anti-CD20 monoclonal antibody-conjugated 1,2-distearoyl-sn-glycero-3-phosphoe-thanolamine-N-methoxypolyethylene-glycol-2000 delivers doxorubicin active carbon nanoparticles to the target CD20 receptor. It exhibited higher cytotoxic activity against CD20-positive human Burkitt’s lymphoma cells (Raji) compared with non-targeted nanoparticles.Citation45 The anti-CD47 monoclonal antibody-conjugated iron oxide magnetic nanoparticle delivering gemcitabine to the target CD47 receptor was shown to increase drug cellular uptake by human pancreatic ductal adenocarcinoma cells (Panc215 and Panc354). Their cytotoxic activity was also significantly enhanced.Citation46 The EGFR antibody-conjugated PLGA nanoparticle delivering rapamycin was shown to exhibit higher cellular uptake by EGFR-overexpressing human breast adenocarcinoma cells (MCF-7) with enhanced cell apoptotic activity against all cell stages.Citation47 For traditional/herbal medicines, the anti-annexin A2 antibody-conjugated PLGA nanoparticle delivering curcumin was shown to significantly increase compound cellular uptake by human breast adenocarcinoma cells (MDA-MB-231).Citation64
Aptamers
Aptamers are short single-stranded DNA or RNA sequences that can fold to three-dimensional structure and bind to specific targets on the cancer cell surfaces that express specific targets for different aptamers. For instance, nucleolin receptor is specific for AS14111 aptamer and EpCAM protein is specific for EpCAM aptamer. The aptamer AS14111-conjugated PEG-PLGA nanoparticle delivering gemcitabine to target nucleolin receptor was shown to increase drug cellular uptake (36%) by nucleolin-overexpressing human lung cancer cells (A549) compared with non-targeted nanoparticles, with enhanced cytotoxic activity (IC50: 4.9 µg/mL and 28.9 µg/mL, respectively).Citation49 The AS14111-conjugated undecylenic acid modified, thermally hydrocarbonized porous silicon (UnTH-CPSi) nanoparticle delivering methotrexate was shown to increase drug cellular uptake by nucleolin-overexpressing human breast adenocarcinoma cells (MDA-MB-231) with enhanced cytotoxic activity compared with non-targeted nanoparticles and nucleolin-negative fibroblasts cells (NIH 3T3).Citation50 The aptamer AS14111-conjugated polymersome delivering doxorubicin was shown to increase drug cellular uptake by nucleolin-overexpressing human breast adenocarcinoma cells (MCF-7) with enhanced cytotoxic activity compared with mutated aptamer-conjugated nanoparticles (mean IC50: 210.9 ng/mL and 369.4 ng/mL, respectively). In addition, it also produced significant tumor growth inhibition in MCF-7 tumor-bearing mice compared with mutated aptamer-conjugated nanoparticles.Citation52 For traditional/herbal medicines, the EpCAM aptamer-conjugated lipid-polymer-lecithin hybrid delivering curcumin was shown to increase compound cellular uptake by EpCAM-overexpressing human colon adenocarcinoma cells (HT29) compared with EpCAM-negative human embryonic kidney cells (HEK293T), (58.9%±2.6% and 72.4%±1.3%, respectively.Citation65
Carbohydrates or polysaccharides
Galactose is one of targeting ligands in group of carbohydrates that is widely used as a targeting agent for nanoparticles. It is specifically recognized by the asialoglycoprotein receptor (ASGPR), which is overexpressed on liver cancer cell surface.Citation54 The galactose-conjugated lithocholic acid-PEG-lactobionic acid nanoparticles delivering doxorubicin was shown to increase drug cellular uptake by human liver cancer cells (SK-HEP-1) leading to massive cell death and tumor growth inhibition compared with non-targeted nanoparticles.Citation54 The galactose-conjugated pectin nanoparticle delivering 5-fluorouracil was shown to increase drug cellular uptake by human hepatocellular liver carcinoma cells (HepG2) with enhanced cytotoxic activity compared with free drug (mean IC50: 0.17×10−4 mol/L and 0.45×10−4 mol/L, respectively). Moreover, the targeted nanoparticle also improved pharmacokinetic profile of the drugs.Citation55 On the other hand, the lactose-conjugated nanoparticle delivering doxorubicin was shown to improve drug efficacy, but not as good as galactose.Citation53 The galactose conjugates not only specifically bind to ASGPR but also to lectin receptor, which is overexpressed on the alveolar macrophages, liver endothelial Kupffer cells, splenic macrophages, peritoneal macrophages, and macrophages of brain. The galactose-conjugated solid lipid nanoparticles delivering doxorubicin specifically targeted human lung cancer cells (A549) resulting in higher cellular uptake, enhanced cytotoxic activity, and improved pharmacokinetic profiles compared with non-targeted nanoparticles and free drug.Citation57
Controlled drug release of active targeting nanoparticles
Controlled drug release is a property of drug delivery systems in cancer therapy. Drugs are delivered and released at specific location to avoid side effects to normal cells.Citation72 Most studies included in this review showed biphasic characteristics of drugs released from both targeted and non-targeted nanoparticles, ie, initial burst release, followed by sustained release. For instance, about 48% and 46% of gemcitabine were released from folic acid-conjugated bovine serum albumin nanoparticles and non-targeted nanoparticles during the first 2 hours, respectively. Sustained release of up to 99% and 94% was observed at 36 hours and pH 7.4 after burst release of targeted and non-targeted nanoparticles, respectively.Citation38 About 22% and 29% of doxorubicin were shown to release from galactose-conjugated solid lipid nanoparticles and non-targeted nanoparticles during the first 8 hours, respectively. After burst release, sustained released was observed up to 76% and 93% at 144 h and pH 7.4 for targeted and non-targeted nanoparticles, respectively.Citation57 Moreover, in some cases, the amount of drug released from nanoparticles at endolysosomal environment (pH 5.5) or cancer cell environment (pH 6.8) was shown to be higher than that from physiological environment (pH 7.4). Up to 60% of doxorubicin was released from anti-CD20-conjugated active carbon nanoparticles and non-targeted nanoparticles at 12 hours and at pH 5.5. At pH 7.4, on the other hand, the release from nanoparticles was only 20%.Citation45 Similarly, about 28% and 24% of gemcitabine burst were released during the first 24 hours from AS1411 aptamer-conjugated PEG-PLGA nanoparticles and non-targeted nanoparticles, respectively. After burst release, up to 44% and 41% sustained release were observed in both formulations at 120 hours and pH 5.5 for targeted and non-targeted nanoparticles, respectively. Only 30% release was observed at pH 7.4.Citation49 In another study, doxorubicin released from chondroitin sulfate A-deoxycholic acid at day 6 was 92%, 53%, and 34% for pH 5.5, 6.8, and 7.4, respectively.Citation60 These results suggested that conjugation of targeting ligands on the surface of nanoparticles did not affect drug release from nanoparticles. Furthermore, higher amount of drug released at acidic pH would benefit the delivery of cancer chemotherapeutic agents to cancer cells with lower side effects to normal cells.
Conclusion
Active targeting nanoparticles of chemotherapeutic drugs or traditional/herbal medicines have been demonstrated in various studies both in vitro and in vivo to improve selectivity of cellular uptake of drugs to cancer cells through receptor-mediated endocytosis and/or cytotoxicity. They provide several advantages over the conventional chemotherapeutic drugs and non-targeted nanoparticle platform, particularly in regard to enhancement of drug efficacy and safety. Active targeting nanoparticles possess several advantages in cancer therapy including enhancement of selectivity of drugs to cancer cells to avoid side effects to normal cells, enhancement of drug accumulation and anticancer activity in cancer cells, and efficiency in control of drug release. Nevertheless, some disadvantages of active targeting nanoparticles include their limitation of clinical uses in only certain types of cancer that express specific receptors on the cell surfaces. Moreover, manufacturing of nanoparticle platforms is costly and requires sophisticated technology. Selection of the types of targeting nanoparticles is determined by the types of target proteins or receptors expressed on cancer cell surfaces. Clinical studies are required to confirm their application in cancer patients.
Acknowledgments
The authors would like to thank the Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine at Thammasat University, Rangsit Center, for providing all the necessary support in conducting this systematic review.
Disclosure
The authors report no conflicts of interest in this work.
References
- SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
- KuppensIEBoschTMvan MaanenMJOral bioavailability of docetaxel in combination with OC144-093 (ONT-093)Cancer Chemother Pharmacol2005551727815316750
- VandanaMSahooSKLong circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancerBiomaterials201031359340935620851464
- YuHTangZZhangDPharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapyJ Control Release2015205899725529533
- ChoKWangXNieSChenZGShinDMTherapeutic nanoparticles for drug delivery in cancerClin Cancer Res20081451310131618316549
- ZhuangYDengHSuYAptamer-functionalized and backbone redox-responsive hyperbranched polymer for targeted drug delivery in cancer therapyBiomacromolecules20161762050206227113017
- WuGWangZBianXDuXWeiCFolate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapyPharm Biol201452897898225017652
- QiXFanYHeHWuZHyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneouslyCarbohydr Polym201512623123925933544
- WangYSongDCostanzaFTargeted delivery of tanshinone IIA-conjugated mPEG-PLGA-PLL-cRGD nanoparticles to hepatocellular carcinomaJ Biomed Nanotechnol201410113244325226000384
- ZhaoYLinDWuFDiscovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug deliveryInt J Mol Sci20141510175651757625268623
- YangBNiXChenLHonokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinomaDrug Deliv201724166066928368206
- GrayBPMcGuireMJBrownKCA liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or densityPLoS One201388e7293824009717
- GaoHZhangSYangZCaoSJiangXPangZIn vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptideInt J Pharm20144661–281724607217
- NamgungRMi LeeYKimJPoly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapyNat Commun20145370224805848
- YangNJiangYZhangHActive targeting docetaxel-PLA nanoparticles eradicate circulating lung cancer stem-like cells and inhibit liver metastasisMol Pharm201512123223925418453
- HongMZhuSJiangYNovel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticlesJ Control Release20101411222919735683
- NagMGajbhiyeVKesharwaniPJainNKTransferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cellsColloids Surf B Biointerfaces201614836337027632697
- JiangXShaXXinHSelf-aggregated pegylated poly (trim-ethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumorsBiomaterials201132359457946921911250
- NazliCDemirerGSYarYAcarHYKizilelSTargeted delivery of doxorubicin into tumor cells via MMP-sensitive PEG hydrogel-coated magnetic iron oxide nanoparticles (MIONPs)Colloids Surf B Biointerfaces201412267468325183059
- GaoYZhouYZhaoLEnhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micellesActa Biomater20152312713526013038
- HuGZhangHZhangLRuanSHeQGaoHIntegrin-mediated active tumor targeting and tumor microenvironment response dendrimer-gelatin nanoparticles for drug delivery and tumor treatmentInt J Pharm201549621057106826598487
- KulhariHPoojaDShrivastavaSNaiduVGMSistlaRPeptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxelColloids Surf B Biointerfaces201411716617324632389
- LiuCWLinWJPolymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicinInt J Nanomedicine201274749476722973097
- TaheriADinarvandRAtyabiFEnhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptideInt J Mol Sci20111274591460821845098
- HuGChunXWangYHeQGaoHPeptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatmentOncotarget2015638412584127426517810
- CaiLQiuNLiXA novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cellsInt J Pharm20114081–217318221277964
- YinSHuaiJChenXIntracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acidActa Biomater20152627428526300335
- SuhMSShenJKuhnLTBurgessDJLayer-by-layer nanoparticle platform for cancer active targetingInt J Pharm20175171–2586627923697
- FreagMSElnaggarYSAbdelmonsifDAAbdallahOYLayer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of rapamycinNanomedicine (Lond)201611222975299627785978
- UpadhyayKKMishraAKChuttaniKThe in vivo behavior and antitumor activity of doxorubicin-loaded poly (γ-benzyl l-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c miceNanomedicine201281718021703363
- MizrahySGoldsmithMLeviatan-Ben-AryeSTumor targeting profiling of hyaluronan-coated lipid based-nanoparticlesNanoscale2014673742375224569711
- XiongHDuSNiJZhouJYaoJMitochondria and nuclei dual-targeted heterogeneous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicinBiomaterials201694708327105438
- ChoHJYoonISYoonHYPolyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicinBiomaterials20123341190120022074664
- ZhongYZhangJChengRReversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenograftsJ Control Release201520514415425596560
- SunBDengCMengFZhangJZhongZRobust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materialsActa Biomater20164522323327576338
- TaoWZhangJZengXBlended nanoparticle system based on miscible structurally similar polymers: a safe, simple, targeted, and surprisingly high efficiency vehicle for cancer therapyAdv Healthc Mater2015481203121425800699
- ChengLHuQChengLConstruction and evaluation of PAMAM-DOX conjugates with superior tumor recognition and intracellular acid-triggered drug release propertiesColloids Surf B Biointerfaces2015136374526360738
- DubeyRDAlamNSanejaADevelopment and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabineInt J Pharm20154921–2809126165611
- JiJZuoPWangYLEnhanced antiproliferative effect of carboplatin in cervical cancer cells utilizing folate-grafted polymeric nanoparticlesNanoscale Res Lett201510145326608536
- YeWLDuJBZhangBLCellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticlesPLoS One201495e9735824828815
- MorelliCMarisPSisciDPEG-templated mesoporous silica nanoparticles exclusively target cancer cellsNanoscale2011383198320721725561
- YinJJSharmaSShumyakSPSynthesis and biological evaluation of novel folic acid receptor-targeted, β-cyclodextrin-based drug complexes for cancer treatmentPLoS One201385e6228923658721
- LiangCYangYLingYHuangYLiTLiXImproved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinomaBioorg Med Chem201119134057406621641806
- McCarronPAMaroufWMQuinnDJAntibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cellsBioconjug Chem20081981561156918627195
- JiangSWangXZhangZCD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cellsInt J Nanomedicine20161155055518 eCollection 201627843311
- TrabuloSAiresAAicherAHeeschenCCortajarenaALMultifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cellsBiochim Biophys Acta2017186161597160528161480
- AcharyaSDilnawazFSahooSKTargeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapyBiomaterials200930295737575019631377
- KouchakzadehHShojaosadatiSAMohammadnejadJPaknejadMRasaeeMJAttachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cellsHum Antibodies2012213–4495623549021
- AlibolandiMRamezaniMAbnousKHadizadehFAS1411 Aptamer-decorated biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersomes for the targeted delivery of gemcitabine to non-small cell lung cancer in vitroJ Pharm Sci201610551741175027039356
- ZhangFCorreiaAMäkiläEReceptor-mediated surface charge inversion platform based on porous silicon nanoparticles for efficient cancer cell recognition and combination therapyACS Appl Mater Interfaces2017911100341004628248078
- XuGYuXZhangJRobust aptamer–polydopamine-functionalized M-PLGA–TPGS nanoparticles for targeted delivery of docetaxel and enhanced cervical cancer therapyInt J Nanomedicine2016112953296527382282
- LiXZhuXQiuLConstructing aptamer anchored nanovesicles for enhanced tumor penetration and cellular uptake of water soluble chemotherapeuticsActa Biomater20163526927926873366
- MouQMaYZhuXYanDA small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapyJ Control Release2016230344427040815
- SinghBJangYMaharjanSCombination therapy with doxorubicin-loaded galactosylated poly(ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancerBiomaterials201711613014427914985
- YuCYWangYMLiNMIn vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapyMol Pharm201411263864424383625
- LiangHFChenSCChenMCLeePWChenCTSungHWPaclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system against cultured HepG2 cellsBioconjug Chem200617229129916536458
- JainAKesharwaniPGargNKGalactose engineered solid lipid nanoparticles for targeted delivery of doxorubicinColloids Surf B Biointerfaces2015134475826142628
- SandovalMASloatBRLansakara-PDSEGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activityJ Control Release2012157228729621871505
- TalelliMOliveiraSRijckenCJIntrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapyBiomaterials20133441255126023122804
- LeeJYChungSJChoHJKimDDBile acid-conjugated chondroi-tin sulfate A-based nanoparticles for tumor-targeted anticancer drug deliveryEur J Pharm Biopharm20159453254126149228
- ChenCHuHQiaoMAnti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrierJ Drug Target201523431132225539074
- ZhangLYaoJZhouJWangTZhangQGlycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugsInt J Pharm20134411–265466423117024
- KesharwaniPBanerjeeSPadhyeSSarkarFHIyerAKHyaluronic acid engineered nanomicelles loaded with 3,4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cellsBiomacromolecules20151693042305326302089
- ThamakeSIRautSLRanjanAPGryczynskiZVishwanathaJKSurface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapyNanotechnology201122303510121149963
- LiLXiangDShigdarSEpithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cellsInt J Nanomedicine201491083109624591829
- JeongJYHongEHLeeSYBoronic acid-tethered amphiphilic hyaluronic acid derivative-based nanoassemblies for tumor targeting and penetrationActa Biomater20175341442628216300
- BazakRHouriMEl AchySKamelSRefaatTCancer active targeting by nanoparticles: a comprehensive review of literatureJ Cancer Res Clin Oncol2015141576978425005786
- CornelioDBRoeslerRSchwartsmannGGastrin-releasing peptide receptor as a molecular target in experimental anticancer therapyAnn Oncol20071891457146617351255
- MasterAMSen GuptaAEGF receptor-targeted nanocarriers for enhanced cancer treatmentNanomedicine (Lond)20127121895190623249333
- KapoorAKumarSCancer stem cell: a rogue responsible for tumor development and metastasisIndian J Cancer201451328228925494123
- ZwickeGLMansooriGAJefferyCJUtilizing the folate receptor for active targeting of cancer nanotherapeuticsNano Reviews2012310.3402/nano.v3403i3400.18496
- RodzinskiAGuduruRLiangPTargeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticlesSci Rep201662086726875783